Pyxis Oncology, Inc.(PYXS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Pyxis Oncology, Inc. (PYXS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PYXS at 11.3/100 on a 32-signal composite quality model, placing it at rank #2,901 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of PYXS by reported 13-F value include GordonMD Global Investments, PFIZER, Laurion Capital Management, based on the most recent SEC filings. PYXS trades on the Nasdaq exchange and files with the SEC under CIK 1782223. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PYXS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pyxis Oncology, Inc. directly from SEC EDGAR.

AI Quality Score

11.3/100

AI Rank

#2,901

Net Income

$-25.3M

PYXS key financials by period

Pyxis Oncology, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202510-K$13.9M$-79.6M—
FY 202410-K$16.1M$-77.3M—

Institutions holding PYXS

Institutional investors reporting a position in Pyxis Oncology, Inc. on SEC Form 13F.
InstitutionSharesValueReported
GordonMD Global Investments10,024,909$30.2M2026-06-30
PFIZER7,032,770$19.5M2026-06-30
Laurion Capital Management4,900,888$14.8M2026-06-30
VANGUARD CAPITAL MANAGEMENT2,075,997$6.2M2026-06-30
HealthInvest Partners AB966,459$2.9M2026-06-30
BlackRock867,934$2.6M2026-06-30
Palo Alto Investors864,277$2.6M2026-06-30
MARSHALL WACE, LLP830,544$2.5M2026-06-30
RENAISSANCE TECHNOLOGIES772,232$2.3M2026-06-30
GEODE CAPITAL MANAGEMENT591,849$1.8M2026-06-30
SEC EDGAR: CIK 1782223 →
PYXS

Pyxis Oncology, Inc.

PYXS
NasdaqSmall CapHealthcare

13F Pro Quality Score

11.3/100

Rank #2,901 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-25.35M

EPS (Diluted)

Q2 2026
EDGAR

$-0.40

Top Institutional Holders

as of Q2 2026
$102.84M total
GordonMD Global Investments LP
$30.17M+143.2%
PFIZER INC
$19.48M0.0%
Laurion Capital Management LP
$14.75M-1.9%
VANGUARD CAPITAL MANAGEMENT LLC
$6.25M+2.1%
HealthInvest Partners AB
$2.91M+390.5%
BlackRock, Inc.
$2.61M+10.0%
Palo Alto Investors LP
$2.60M-14.5%
MARSHALL WACE, LLP
$2.50M+134.3%
RENAISSANCE TECHNOLOGIES LLC
$2.32M-13.1%
GEODE CAPITAL MANAGEMENT, LLC
$1.78M-1.0%

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…